The role of dopamine receptors in lymphocytes and their changes in schizophrenia

M.A. Penedo a, T. Rivera-Baltanás a, D. Pérez-Rodríguez a, J. Allen b, A. Borrajo c,d, D. Alonso-Crespo b,e, C. Fernández-Pereira a, M. Nieto-Araujo a,f, S. Ramos-García a,f, C. Barreiro-Villar a,f, H.J. Carunch b, J.M. Olivares a,g, R.C. Agís-Balboa a,*

a Translational Neuroscience Group-CIBERSAM, Galicia Sur Health Research Institute (IIS Galicia Sur), Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, Vigo, Spain
b Division of Medical Sciences, University of Victoria, Victoria, BC, Canada
c Department of Microbiology and Parasitology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain
d Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Roma, Italy
e Nursing Team - Intensive Care Unit, Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro SERGAS-UVigo, Vigo, Spain
f Nursing Team - Acute Psychiatry Unit, Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, Vigo, Spain
g Department of Psychiatry, Área Sanitaria de Vigo-Hospital Álvaro Cunqueiro, Vigo, Spain

ARTICLE INFO

Keywords:
Schizophrenia
Psychosis
Dopamine
Dopamine receptors
Lymphocytes

ABSTRACT

Dopamine and its 5 receptors, which are grouped into two families (D1-like and D2-like), modulate functions at a systemic level in both the central nervous system and periphery. The central nervous system and the immune system are the main adaptive systems, which participate in a continuous and functional crosstalk to guarantee homeostasis. On binding to its 5 dopamine receptors, dopamine acts as a co-regulator of the immune system, contributing to the interaction of the central nervous system and inflammatory events and as a source of communication between the different immune cells. Dopaminergic perturbations in the central nervous system are observed in several neurological and psychiatric disorders. Schizophrenia is one of the most common mental disorders with a poorly understood pathoetiology that includes genetic and environmental components that promote alterations in the dopaminergic system. Interestingly, abnormalities in dopamine receptors expression in lymphocytes of schizophrenia patients have been reported, often significantly correlating with the severity of the psychotic illness. Here, we review the current literature regarding the dopaminergic system in human lymphocytes and its alterations in schizophrenia.

1. Introduction

Dopamine (DA) is part of the catecholamine family and was first synthesized in 1910 by George Barger and James Ewens (Barger and Dale, 1910; Mannich et al., 1910). Later, DA was found to be an important member of the group of neurotransmitters called biogenic amines and have primary functions and a remarkable distribution in the brain and as well as the rest of the body (Roe, 1999). The effects of DA are mediated by the union of the primary endogenous ligand with the DA receptors (DRs).

There are 5 major subtypes of DRs that belong to a superfamily of metabolotropic G-protein-coupled receptors of seven A-class transmembrane domains (Harmar et al., 2009), divided into two families according to their pharmacological profile. The D1-like receptor subtypes (D1R and D5R) are stimulatory receptors coupled to the Gαs-protein and the D2-like receptor subtypes (D2R, D3R and D4R) are inhibitory receptors coupled to the Gαi/o-protein, depending on their ability to subsequently activate the enzyme adenyl cyclase, increasing or not the intracellular concentration of the secondary messenger cyclic adenosine monophosphate (cAMP), respectively (Kebabian, 1978; Beaulieu et al., 2015; Spano et al., 1978). Interestingly, DRs can form heterodimers leading to a particularly organized, varying combinatorial possibilities at a higher level, which gives this family of receptors very diverse pharmacological and functional properties (Beaulieu et al., 2015).

DA is best known for its role as a neurotransmitter, participating in a wide variety of functions in the brain including; control of movement, behaviour, motivation, cognition, and reward. Dopaminergic neurons primarily synthesize DA and are located within the substantia nigra pars
compacta and ventral tegmental area in the mesencephalon. Dopaminergic projections form a large network of connections through 3 pathways that begin in the midbrain: the nigrostriatal pathway which innervates dorsal areas, the mesolimbic which projects to ventral areas, while prefrontal cortical areas are reached via mesocortical pathway projections (Kandel et al., 2000; Cave and Baker, 2009). In addition, there is a fourth pathway called tuberoinfundibular that connects the hypothalamus to the anterior pituitary to inhibit prolactin secretion (Porter et al., 1990).

Given that DA cannot cross the blood-brain-barrier, the existence of DA in the bloodstream suggests the presence of dopaminergic components that modulate functions at a systemic level; therefore, its effects are not limited to the central nervous system (CNS) and the signalling in the neuronal dopaminergic system should be independent from that of the peripheral systems (Rubí and Maechler, 2010; Arreola et al., 2016). Plasma DA levels are regulated primarily by their release from sympathetic nerve fibbers, which innervate the secondary lymphoid tissues that store high concentrations of DA. Under physiological conditions, plasma DA levels are estimated to be ~ 10^{-16} M − 10^{-11} M. The 5 DRs are co-expressed at different quantities and in numerous combinations in the CNS and peripheral tissues (Kirillova et al., 2008). Both primate and rodent brains express a higher density of D1-like than D2-like subtypes in healthy conditions (Weinstein et al., 2017).

The CNS and the immune system are the main adaptive systems, which participate in a continuous and functional crosstalk to guarantee homeostasis (Arreola et al., 2016; Franco et al., 2007; Basu and Dasgupta, 2000). By binding to its receptors, DA acts as a co-regulator of the immune system, contributing to the interaction between the immune cells and the CNS and as a source of communication between the different immune cells (Arreola et al., 2016; Franco et al., 2007; Basu and Dasgupta, 2000; Sarkar et al., 2010; Levite and Levite, 2012; Rodrigues-Amorim et al., 2018; Stahl, 2017a).

Dopaminergic perturbations in the CNS are observed in several neurological and psychiatric disorders (Stahl, 2017a; Grace, 2016). Schizophrenia (SCZ) is one of the most common mental disorders that affects about one per cent of the world’s population. SCZ is a chronic and frequently disabling syndrome with a poorly understood pathoetiology, that includes genetic and environmental components promoting alterations in the dopaminergic system (Silfstein et al., 2015; Marder and Cannon, 2019). Interestingly, abnormalities in the expression of DRs in lymphocytes (LYM) of schizophrenic patients have been reported, which often significantly correlate with psychotic illness severity (Liu et al., 2013). Here, we review the current literature pertaining to the dopaminergic system in human LYM and how it is altered in one of the main psychiatric diseases, SCZ. Information was gathered by searching the PubMed Services database using the following keywords: dopamine, dopamine receptors, lymphocytes, schizophrenia. We have also included relevant articles referenced in the bibliographies from all the articles searched as well as historically remarkable or conceptually related articles.

2. Dopamine receptors in lymphocytes

LYM are the principal cells of the adaptive immune system that differentiate into many subpopulations with a wide variety of functions. These cells can modulate, regulate and coordinate the activities of other immune cell populations through cytokine secretion, and at the same time, can respond to electrolyte, levels of cytokines, hormones, and neurotransmitters (Levite and Levite, 2012; Rodrigues-Amorim et al., 2018; Bergquist et al., 1994). The effects by DA-mediated activation of the different DRs on diverse immune cell types show different sensitivities to DA, but the binding profiles of DA on T cells are similar to those in neuronal membranes, suggesting the receptors act similarly to those found in neurons (Matt and Gaskill, 2020).

The idea that neurotransmitters could serve as immunomodulators came with the finding that their discharge and diffusion from nervous tissue could give rise to signalling through LYM membrane receptors and modulation of immune function (Franco et al., 2007). In the late 20th century, several studies showed that LYM have the metabolic capacity to synthesize DA and its metabolites, although at a very low concentration of ~10^{-18} mol/cell, and the DRs are present as functional receptors on the cell surface, that bind and respond to DA and its analogues (Bergquist et al., 1994). The main source of DA could be within the immune system itself, as the immune cells can capture circulating plasma DA through active transport using DAT, a Na+/-dependent DA transporter (Faraj et al., 1994; Amenta et al., 2001; Marino et al., 1999; Pacheco et al., 2009), and release it in physiological and pathological conditions, acting as an autocrine/paracrine modulator in immune cells and neighbouring cells (Arreola et al., 2016; Basu and Dasgupta, 2000; Liu et al., 2013; Pacheco et al., 2009; Faraj et al., 1991). LYM regulate their DA concentration very finely, holding it at a basal level of 1.6 × 10^{-18} mol/cell, through a balance between the internal, its synthesis and transported DA.

Searching for DA receptors on LYM has been a challenging mission. Using different laboratory techniques, such as: flow cytometry (Kustrimovic et al., 2014; McKenna et al., 2002; Levite, 2016), RT-PCR and qRT-PCR (Kirillova et al., 2008; Bondy et al., 1996; Arce-Sillas et al., 2019; Ostadali et al., 2004), radio ligand binding assays (Kirillova et al., 2008; Amenta et al., 1999; Santambrogio et al., 1993; Ricci et al., 1997) and western blot (Franco et al., 2007), it has been observed that all DRs are differentially expressed in almost all LYM lineages. Although, in most reports only some types of immune cells and some types of DRs were studied.

DA can affect most, if not all immune cells and the expression of all DRs depends on the state of cellular activation and concentration and the time of exposure to DA (Sarkar et al., 2010; Levite and Levite, 2012; Kustrimovic et al., 2014). DRs mRNA and protein levels vary among immune cell subpopulations: T LYM and monocytes have the lowest DR expression, neutrophils and eosinophils a moderate expression, while B LYM and NK cells have the highest and most consistent levels (McKenna et al., 2002; Levite, 2016; Arce-Sillas et al., 2019). Work by McKenna et al. tells that some immune cells have higher levels of DRs than others, where the expression of D3R and D5R is stable and always detected in LYM, while the expression of D2R and D4R is more variable, but D1R expression was not revealed (McKenna et al., 2002). 5 years later, D1R expression was demonstrated in effector and regulatory T cells (Costenino et al., 2007; Nakano et al., 2008).

In a very interesting study (Kirillova et al., 2008), the expression levels of DRs in the brain were compared with those of peripheral blood mononuclear cells (PBMCs), and it was revealed that the expression levels of mRNA of D3R and D4R in the PBMCs were equivalent with those in the brain for these receptors, and were significantly lower for mRNA of D2R and D3R. However, the relative expression of DRs in LYM was not parallel to that of the brain.

In summary, it can be confirmed that all DRs are expressed on the LYM membrane. However, more detailed information is required on the expression patterns of DR in immune cells in healthy conditions and in pathologies, regarding the differences between cell subsets and the relationship to the functional status of cells.

3. Effects of dopamine on lymphocytes

It has been proposed that DA could be referred to as a ‘neuro-immune-transmitter’, because in the last 2 decades direct and potent DA-induced functions in most immune cells have been discovered, many of them of high importance (Levite and Levite, 2012). The most notable immuno-modulatory functions of DA are carried out during the immune response, where DA selectively regulates the activation of different phenotypes of LYM and the communication between immune cells (Kustrimovic et al., 2014; Nakano et al., 2008; Kipnis et al., 2004). DA has been observed to influence LYM functions acting in a variety of important processes, like cytokine secretion, cell adhesion, chemotaxis, and cytotoxicity (Arreola et al., 2016; Arce-Sillas et al., 2019; Levite
A. Concentrations of DA: different DA concentrations often induce different and even opposite effects in immune cells. At a normal concentration of ~10^{-8} M (0.1 nM), DA usually produces specific and physiological effects, but when this concentration is at a very high level of ~10^{-2} M (0.1–10 mM), then nonspecific and even toxic effects are induced on oxidative metabolism in immune cells, often evoking apoptosis (Matt and Gaskill, 2020; Cosentino et al., 2004, 2007). Monocyte-derived dendritic cells store DA in secretory vesicles, and antigen-specific interaction with naïve CD4^{+} T cells induces the release of this DA (Nakano et al., 2009).

B. The activation state of the immune cell: DA frequently activates naïve immune cells, especially T cells, but DR activation by DA or other stimuli inhibits activated immune cell function (Levite and Levite, 2012; Vidal and Pacheco, 2020):

C. The specific type of the immune cell: DA on its own activates naïve normal human T cells, and drives them to function (Levite et al., 2001; Cosentino et al., 2004; Besser et al., 2005; Watanabe et al., 2006). They are also associated with an immune regulatory response (Nakano et al., 2009), activating the production of inflammatory TNF{\alpha} by D3R stimulation and anti-inflammatory IL-10 by D2R stimulation in T and B LYM, respectively (Besser et al., 2005). On the contrary, it seems that D4R signalling induces T cell inactivity and is not expressed in CD19^{+} B LYM (Watanabe et al., 2006), where D4R agonists down regulate the proliferation and IL-2 secretion of activated T cells (CD3^{+}CD28^{+}) (Sarkar et al., 2006).

Stimulation of D2R in activated CD4^{+} T cells causes a Th2 to Th1 swing, and trigger IFN{\gamma} production in activated CD8^{+} T cells (Ilani et al., 2016; Franco et al., 2007; Watanabe et al., 2006; Zhao et al., 2013; Huang et al., 2016).

In T LYM, the binding of DA to D2R and D3R produces an increase in trafficking dependent on integrins, resulting in a stimulation of chemotaxis migration, selective adhesion to extracellular matrix, and homing of activated CD8^{+} cytotoxic T cells in the periphery (Levite et al., 2001; Watanabe et al., 2006). They are also associated with an immune regulatory response (Nakano et al., 2009), activating the production of inflammatory TNF{\alpha} by D3R stimulation and anti-inflammatory IL-10 by D2R stimulation in T and B LYM, respectively (Besser et al., 2005). On the contrary, it seems that D4R signalling induces T cell inactivity and is not expressed in CD19^{+} B LYM (Watanabe et al., 2006), where D4R agonists down regulate the proliferation and IL-2 secretion of activated T cells (CD3^{+}CD28^{+}) (Sarkar et al., 2006).

3.2. DA on D2-like receptors

In contrast, most of the immunostimulatory DA effects on LYM depend on stimulation of D2-like receptors (Fig. 1B), including activation, proliferation, differentiation, and suppression of NK cells (Arreola et al., 2001; Cosentino et al., 2004; Besser et al., 2005; Watanabe et al., 2006; Nakano et al., 2009).

The overall effects of DA on LYM depends on the context in accordance to the following parameters (Levite and Levite, 2012; Vidal and Pacheco, 2020):

A. Concentrations of DA: different DA concentrations often induce different and even opposite effects in immune cells. At a normal concentration of ~10^{-8} M (0.1 nM), DA usually produces specific and physiological effects, but when this concentration is at a very high level of ~10^{-2} M (0.1–10 mM), then nonspecific and even toxic effects are induced on oxidative metabolism in immune cells, often evoking apoptosis (Matt and Gaskill, 2020; Cosentino et al., 2004, 2007). Monocyte-derived dendritic cells store DA in secretory vesicles, and antigen-specific interaction with naïve CD4^{+} T cells induces the release of this DA (Nakano et al., 2009).

B. The activation state of the immune cell: DA frequently activates naïve immune cells, especially T cells, but DR activation by DA or other stimuli inhibits activated immune cell function (Levite and Levite, 2012; Vidal and Pacheco, 2020):

C. The specific type of the immune cell: DA on its own activates naïve normal human T cells, and drives them to function (Levite et al., 2001; Cosentino et al., 2004; Besser et al., 2005; Watanabe et al., 2006). They are also associated with an immune regulatory response (Nakano et al., 2009), activating the production of inflammatory TNF{\alpha} by D3R stimulation and anti-inflammatory IL-10 by D2R stimulation in T and B LYM, respectively (Besser et al., 2005). On the contrary, it seems that D4R signalling induces T cell inactivity and is not expressed in CD19^{+} B LYM (Watanabe et al., 2006), where D4R agonists down regulate the proliferation and IL-2 secretion of activated T cells (CD3^{+}CD28^{+}) (Sarkar et al., 2006).

Stimulation of D2R in activated CD4^{+} T cells causes a Th2 to Th1 swing, and trigger IFN{\gamma} production in activated CD8^{+} T cells (Ilani et al., 2004). D3R signalling in T cells enhances their activation, favouring differentiation towards Th1 phenotype and mutually buffering the acquisition of the Th2 phenotype (Franz et al., 2015; González et al., 2013; Contreras et al., 2016). A recent study revealed that D4R signalling on T cells favours Th2 differentiation (Huang et al., 2016; Wang et al., 2019).

Taken together, these findings indicate that LYM could undergo a complex dopaminergic regulation. It is interesting to note that these immune functions in turn can affect dopaminergic signalling both centrally and peripherally, and dopaminergic neurotransmission is
important to immunoregulation in physiological and pathological conditions. Altered levels of DRs expressed in immune cells, and/or changed response of immune cells to DA, may play a role in some neurological and psychiatric diseases (Huang et al., 2016). It could be thought that, if there are alterations in the neuronal dopaminergic system under pathological conditions, there would also be alterations in the rest of the peripheral dopaminergic systems such as the ones that influences immune cells.

4. Changes in the dopaminergic system of lymphocytes associated with schizophrenia

SCZ is a heterogeneous chronic psychiatric syndrome characterized in its most common form by psychotic or positive symptoms (hallucinations, paranoid delusions and disorganized speech), by negative symptoms (decreased motivation and expressiveness with impaired social interaction), and by cognitive deficits including executive functions, memory and speed of mental processing. SCZ often manifests during late adolescence or early adulthood, and the prevalence of this disorder reaches almost 1% of the world’s population (with an annual incidence that ranges between 3.89 and 4.03 per 1000 subjects) (Moreno-Küstner et al., 2018) and is one of the top 10 global causes of disability with 90% mortality (Saha et al., 2007).

The current diagnosis of SCZ and the establishment of a therapeutic approach are mostly based on clinical questionnaires that confirm that patients meet established criteria for the disorder, such as the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) (American Psychiatric Association, 2013). The clinical response is often characterized for recurrent relapses for those patients who discontinue medication or have changes in the adherence, which are associated with adverse outcomes, including symptoms resistant to treatment, cognitive decline, and chronic functional disability (Marder and Cannon, 2019; Emsley et al., 2013).

The DRs are the most common targets of antipsychotics, such as haloperidol, risperidone or aripiprazole, among others, that modulate DA neurotransmission by receptor occupancy (Slišťen et al., 2015; Marder and Cannon, 2019). However, antipsychotics are not clinically effective at alleviating all symptoms associated with SCZ and may exacerbate cortical-related symptoms, such as negative symptoms and cognitive impairment, including extrapyramidal motor syndromes (Liu et al., 2016). There is a new classification of drugs for psychosis according to which DRs they bind, which have functional differences with potential clinical implications: those that preferentially bind D2R (most of them), D3R and D1R (Stahl, 2017b). To date, an altered expression or signalling of neurotransmitter receptors is observed in immune cells during psychiatric disorders and, consequently, these cells also markedly respond to antipsychotics (Matt and Gaskill, 2020; Faraj et al., 1991; Huang et al., 2016). Taken together, these findings support the involvement of active cross-talk between the dopaminergic and immune systems in the pathophysiology of SCZ (Vidal and Pacheco, 2020).

Besides alterations in the dopaminergic system in the CNS, it has been suggested that the DRs found on LYM may reflect the status of homologous brain DRs (Tomaski et al., 2016; Buttarelli et al., 2011; Rollins et al., 2010). Various aspects of the dopaminergic system have been investigated in peripheral blood samples from patients with SCZ to find reliable peripheral biomarkers of diagnosis and pathological severity (Rodrigues-Amorim et al., 2017), including analysis of the expression of DRs in peripheral blood lymphocytes (PBLs). Interestingly, the expression levels of DRs in LYM of SCZ patients were often significantly different from those in LYM of healthy individuals, but the results have been conflicting (Table 1).

4.1. D1-like receptors

D1R expression in LYM has always been highly controversial. No expression was detected in LYM from patients with SCZ by two groups of researchers (Boneberg et al., 2006; Fernandez-Egea et al., 2016). However, in another article D1R was expressed in 100% of the LYM of healthy controls and treated and drug-naive SCZ patients, but, statistically significant differences were not found between SCZ patients and controls (Ahmadian et al., 2014).

On the other hand, in drug-free SCZ patients that did not take antipsychotics for more than 3 months, D5R mRNA expression in PBLs is increased compared to that of drug-mediated SCZ (Kwak et al., 2001). Little is known about the D5R because, according to some authors, RT-PCR is not possible since it has at least two transcribed pseudogenes, which exhibit high nucleotide sequence homology (approximately 95%) to the functional gene (Takahashi et al., 1992), occasioning a strong limitation in primer design possibilities that do not amplify genomic DNA (Boneberg et al., 2006).

Nevertheless, some reports suggest that the D1R may be related to the negative symptoms (Davidson et al., 1990; Stenkrona et al., 2019) and the fact that the D5R in the PFC is down-regulated by antipsychotics in an animal experiment may suggest that the D5R is also related to SCZ (Lidow et al., 1997).

4.2. D2-like receptors

4.2.1. D2R

Regarding the characterization of the expression patterns of D2R (Table 2), according to one article they are not expressed on leukocytes (Boneberg et al., 2006), but in a study by Ahmadian et al., expression rated in LYM of healthy controls was 6.66%, in drug-free SCZ patients who had not taken antipsychotic drugs for more than 3 months 40% and in patients who had been taking antipsychotic drugs for more than 3 years 20% (Ahmadian et al., 2014). Though, statistical comparison between groups showed no significant differences (Ahmadian et al., 2014; Yao et al., 2008), as was found in T LYM among healthy controls and patients with early psychosis and SCZ/schizophreniform disorder (Cui et al., 2015). On the other hand, another article showed for the first time that the D2R gene in the PBLs was significantly overexpressed in drug-naive/drug-free SCZ patients when compared to healthy controls (Zvara et al., 2005). Since neither the affected nor the non-affected individuals were under antipsychotic treatment or other medication, elevated D2R mRNA levels here reflected the disorder itself rather than the effect of medication (Zvara et al., 2005), as could also be seen in an assay where the specific binding of the DA antagonist 3H-spiperone was significantly increased in LYM from SCZ patients (Bondy et al., 1985).

By means of flow cytometry, increased percentages of CD8+D2R+ cells were observed in SCZ patients hospitalized over a 10-year period and receiving typical antipsychotic treatment, albeit this population revealed lower CD4+D2R+ cells in comparison to controls (Brito-Melo et al., 2012). These results suggest a cell specific alteration of the expression of D2R in the LYM of SCZ patients (Brito-Melo et al., 2012).
Interestingly, a relationship between clinical symptoms and immunological parameters was also observed. The scores of BPRS and PANSS were positively related to CD8⁺ T cells and the Abnormal Involuntary Movement Scale (AIMS) was positively related to CD4⁺ T cells, in institutionalized chronic SCZ patients (Brito-Melo et al., 2012). These relationships are corroborated by other articles which show that there was a significant correlation between mRNA D2R levels in PBLs and the positive symptom score of PANSS in acute SCZ patients experiencing their first episode with an illness duration of less than 1.5 years (Liu et al., 2013), and that symptom severity was related to the excited factor of the PANSS in T LYM of patients with SCZ/schizophreniform disorder (Cui et al., 2015). In chronic SCZ patients, a significant relationship between D2R mRNA levels and positive symptom score of PANSS was not found (Liu et al., 2013).

This result can echo the “DA hyperfunction hypothesis” of SCZ and the idea from psychopharmacology that mutual verification of antipsychotic drugs controls the positive symptoms of SCZ through their effects on D2R (Liu et al., 2013).

### 4.2.2. D3R
The D3R (Table 3) has been the most investigated of all 5 DRs in LYM of SCZ patients. Several studies have examined D3R mRNA levels in LYM in patients with SCZ, but the results are quite conflicting, demonstrating an increase (Ilani et al., 2004; Kwak et al., 2001; Vogel et al., 2004; Boneberg et al., 2006; Ahmadian et al., 2014; Fernandez-Egea et al., 2016), as well as a decrease (Vogel et al., 2004), or no differences (van der Weide et al., 2003; Zvara et al., 2005; Rodrigues et al., 2005; Kawano et al., 2011; Urban-Kucuk et al., 2011). Thus, it is not clear whether D3R mRNA levels are altered in the PBLs of patients with SCZ, and many authors propose it as a biomarker candidate for diagnosing and follow-up of SCZ (Ilani et al., 2004; van der Weide et al., 2003; Ahmadian et al., 2014; Cui et al., 2015).

In general, it seems that D3R is influenced by antipsychotic treatment but not by the different substances taken, typical or atypical (Ilani et al., 2004; van der Weide et al., 2003; Zvara et al., 2005). The discrepancies observed may depend on the intake time, the necessary time to give a positive medication effect or a compensatory response of the receptor blockage due to the administration of antipsychotics, and considering mRNA expression levels of D3R in PBMCs are comparable to those in the brain (Kirillova et al., 2008).

There are significant differences between naïve patients with early psychosis and SCZ, who had never taken antipsychotic drugs, and healthy controls (Ahmadian et al., 2014; Cui et al., 2015), an increased in D3R expression being observed in drug-free patients who had not taken antipsychotic drugs for more than 3 months in comparison to controls (Ahmadian et al., 2014) and drug medicated patients for more than 3 years, whom were considered stable (Kwak et al., 2001). Interestingly, antipsychotics medication caused D3R expression to peak at the 2nd week, but decreased its expression later at the 8th week where it continued like this till after 1 year or even 3 years of treatment, becoming similar to those of healthy controls or at least not statistically different (Ilani et al., 2004; Kwak et al., 2001; van der Weide et al., 2003; Vogel et al., 2004; Kawano et al., 2011). This might be caused by down-regulation of D3R production by antipsychotic drug treatment when it reaches the desired effect.

In addition, D3R was detected in CD4⁺ T cells and was found to be significantly increased in SCZ patients taking clozapine, which was correlated with a proportionally reduced frequency of Tregs, in which DR expression is abnormal in patients with treatment-resistant SCZ (Fernandez-Egea et al., 2016). In this group of patients, it could be thought

### Table 1
Findings of DRs expression in LYM of patients with SCZ.

| Reference                        | Findings                                                                 |
|----------------------------------|-------------------------------------------------------------------------|
| Bondy et al., 1985               | Increased D2-like binding (of 3H-spiperone)                              |
| Kwak et al., 2001                | Increased D3R mRNA (drug-free vs medicated and controls)                |
| van der Weide et al., 2003       | No differences in D3R mRNA (drug-free vs drug-naive)                    |
| Ilani et al., 2004               | Increased D3R mRNA in SCZ                                              |
| Vogel et al., 2004               | Reduced D3R mRNA (drug-naive vs controls)                               |
| Zvara et al., 2005               | D2R mRNA over-expressed                                                 |
| Rodrigues et al., 2005          | No differences in D3R and D4R protein levels                            |
| Boneberg et al., 2006           | Significant inverse correlation (BPRS hebephrenic dimension score vs D3R, D4R) |
| Yao et al., 2008                 | No differences in D2R mRNA                                             |
| Kawano et al., 2011             | D3R mRNA inversely correlated with the total PANSS score                |
| Urban-Kucuk et al., 2011        | No differences in D3R mRNA                                             |
| Brito-Melo et al., 2012         | Increased percentages of CD8⁺ D2R⁺ cells                               |
| Liu et al., 2013                 | No differences in D2R mRNA                                             |
| Ahmadian et al., 2014           | Significant relationship between D2R mRNA and positive symptom score of PANSS in acute SCZ patients |
| Cui et al., 2015                 | D3R expressed in all groups, increased mRNA in drug-free patients vs controls and significant differences between drug-naïve patients vs controls |
| Fernandez-Egea et al., 2016     | Significant positive correlation between D2R mRNA vs excited factor of PANSS in SCZ/schizophreniform patients |

**Abbreviations:** Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Abnormal Involuntary Movement Scale (AIMS).
## Table 2
Findings of D2R expression in LYM of patients with SCZ.

| Reference               | Study Description                      | Sample | Methodology | Clinical Features | Findings                                      |
|-------------------------|----------------------------------------|--------|-------------|-------------------|-----------------------------------------------|
| Bondy et al., 1985      | Healthy controls                       | 40 LYM | Receptor binding assay | ND | Increased D2-like binding (of 3H-spiperone) |
|                         | Unmedicated SCZ patients                | 27     |             |                   |                                               |
|                         | Psychiatric control group               | 16     |             |                   |                                               |
| Zvara et al., 2005      | Healthy controls                       | 10 PBLs| qRT-PCR     | PANSS, CGIS, GAF, Duration of illness, Medication | D2R mRNA over-expressed                       |
|                         | Drug-free/Drug-naive SCZ patients       | 13     |             |                   |                                               |
| Boneberg et al., 2006   | Healthy controls                       | 10 Leukocyte population | qRT-PCR | ND | D2R is not expressed                        |
|                         | SCZ patients                           | 10     |             |                   |                                               |
| Yao et al., 2008        | Healthy controls                       | 26 PBLs| qRT-PCR     | Duration of treatment | No differences in D2R mRNA                   |
|                         | First-hospitalized SCZ patients         | 30     |             |                   |                                               |
| Brito-Melo et al., 2012 | Healthy controls                       | 20 LYM (CD4, CD8) | Flow-cytometry | CGIS, BPRS, PANSS, AIMS, Duration of illness and hospitalization, Dose of antipsychotic | Increased percentages of CD8 $^{+}$D2R $^{-}$ cells |
|                         | SCZ patients                           | 40     |             |                   |                                               |
| Liu et al., 2013        | Healthy controls                       | 30 PBLs| qRT-PCR     | PANSS, Duration of illness | No differences in D2R mRNA                   |
|                         | Acute SCZ patients                      | 25     |             |                   |                                               |
| Ahmadian et al., 2014   | Chronic SCZ patients                    | 27 PBLs| RT-PCR      | ND | D2R expressed in all groups but no differences in mRNA |
|                         | Healthy controls                       | 20     |             |                   |                                               |
|                         | Drug-naive SCZ patients                 | 5      |             |                   |                                               |
|                         | Drug-free SCZ patients (∼ 3 months)    | 15     |             |                   |                                               |
|                         | Drug-medicated SCZ patients (∼ 3 years) | 22     |             |                   |                                               |
| Cui et al., 2015        | Healthy controls                       | 30 T LYM | qRT-PCR | Duration of treatment, Medication, Age of onset, PANSS | No differences in D2R mRNA |
|                         | Psychotic not otherwise specified patients | 18     |             |                   |                                               |
|                         | SCZ/schizophreniform patients          | 14     |             |                   |                                               |

Abbreviations: Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Clinical Global Impression Scale (CGIS), Global Assessment of Functioning (GAF), Brief Psychiatric Rating Scale (BPRS), Abnormal Involuntary Movement Scale (AIMS). No Data (ND).
### Table 3
Findings of D3R expression in LYM of patients with SCZ.

| Reference                          | Study                                      | n   | Sample | Methodology | Clinical features                                                                 | Findings                                                                                           |
|------------------------------------|--------------------------------------------|-----|--------|-------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Kwak et al., 2001                  | Healthy controls                           | 31  | PBLs   | RT-PCR      | Age of symptoms onset, Duration of illness, BPRS, ESRS, Dose of antipsychotic, Duration of no medication | Increased D3R mRNA (drug-free vs medicated and controls)                                            |
|                                    | Drug-medicated SCZ patients (-3 years)      | 44  |        |             |                                                                                   | No differences in D3R mRNA (drug-free vs drug-naive)                                              |
|                                    | Drug-free SCZ patients (-3 months)          | 28  |        |             |                                                                                   |                                                                                                    |
|                                    | Drug-naive SCZ patients                     | 15  |        |             |                                                                                   | After taking antipsychotics, D3R peaked at 2nd week, which later at 8th decreased                   |
| van der Weide et al., 2003         | Healthy controls                           | 8   | PBLs   | RT-PCR      | ND                                                                                | No differences in D3R mRNA                                                                          |
|                                    | SCZ patients                                | 8   |        |             |                                                                                   |                                                                                                    |
| Ilani et al., 2004                 | Healthy controls                           | 11  | PBLs   | RT-PCR      | ND                                                                                | Increased D3R mRNA in SCZ                                                                            |
|                                    | SCZ patients                                | 14  |        |             |                                                                                   |                                                                                                    |
| Vogel et al., 2004                 | Healthy controls                           | 12  | PBLs   | RT-PCR      | PANSS, BPRS, MADRS, YMRS                                                          | Reduced D3R mRNA (drug-naïve vs controls)                                                         |
|                                    | Drug-naive SCZ patients                     | 6   |        |             |                                                                                   |                                                                                                    |
|                                    | Drug-free SCZ patients (-4 weeks)           | 9   |        |             |                                                                                   |                                                                                                    |
|                                    | Drug-medicated SCZ patients                 | 9   |        |             |                                                                                   |                                                                                                    |
| Rodrigues et al., 2005             | Healthy controls                           | 45  | PBLs   | Flow-cytometry | BPRS                                                                        | No differences in D3R protein levels                                                                |
|                                    | SCZ patients                                | 45  |        |             |                                                                                   | Significant inverse correlation (BPRS hebephrenic dimension score vs D3R)                           |
| Bonegerg et al., 2006              | Healthy controls                           | 10  | Leukocyte population | qRT-PCR | ND                                                                       | Increased D3R mRNA in T cells                                                                      |
| Kawano et al., 2011                | Healthy controls                           | 12  | PBLs   | qRT-PCR      | PANSS, BACS-J, Treatment dose, Duration of illness                               | No differences in D3R mRNA                                                                           |
|                                    | SCZ patients                                | 11  |        |             |                                                                                   | D3R mRNA inversely correlated with the total PANSS score                                           |
| Urban-Kucuk et al., 2011           | Healthy controls                           | 51  | PBLs   | RT-PCR      | ND                                                                                | No differences in D3R mRNA                                                                           |
|                                    | SCZ patients                                | 55  |        |             |                                                                                   | Significant differences in D3R mRNA (controls vs disorganized SCZ, disorganized SCZ vs paranoid SCZ) |
| Ahmadian et al., 2014              | Healthy controls                           | 20  | PBLs   | RT-PCR      | ND                                                                                | D3R expressed in all groups, increased mRNA in drug-free patients vs controls and significant differences between drug-naive patients vs controls |
|                                    | Drug-naive SCZ patients                     | 5   |        |             |                                                                                   |                                                                                                    |
|                                    | Drug-free SCZ patients (-3 months)          | 15  |        |             |                                                                                   |                                                                                                    |
|                                    | Drug-medicated SCZ patients                 | 22  |        |             |                                                                                   |                                                                                                    |
| Cui et al., 2015                   | Healthy controls                           | 30  | T LYM  | qRT-PCR      | Duration of treatment, Medication, Age of onset, PANSS                           | Significant differences in D3R mRNA (controls vs psychotic and SCZ/schizophreniform patients)       |
|                                    | Psychotic not otherwise specified patients  | 18  |        |             |                                                                                   |                                                                                                    |
|                                    | SCZ/schizophreniform patients               | 14  |        |             |                                                                                   |                                                                                                    |
| Fernandez-Egea et al., 2016       | Healthy controls                           | 18  | LYM    | qRT-PCR      | BMI, Smoking, BACS, CGIS                                                          | Increased D3R mRNA in clozapine-treated SCZ patients                                               |
|                                    | Chronic SCZ patients                        | 18  |        |             |                                                                                   |                                                                                                    |

Abbreviations: Brief Psychiatric Rating Scale (BPRS), Extrapyramidal Symptom Rating Scale (ESRS), Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Montgomery-Asberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), Brief Assessment of Cognition in Schizophrenia (BACS), Body mass index (BMI), Clinical Global Impression Scale (CGIS). No Data (ND).
that since they are resistant to treatment, they would never reach the desired effect that reduces the symptoms of the disease.

Furthermore, negative schizophrenic or depressive symptoms and more severe psychiatric symptoms seemed to correlate with higher D3R levels (Kwak et al., 2001; Vogel et al., 2004). On the other hand, LYM D3R mRNA levels and total PANSS score showed a statistically significant inverse relationship (Kawano et al., 2011). Also there is a significant inverse correlation between BPRS hebbrephic dimension score and D3R expression in LYM of SCZ patients (Rodrigues et al., 2005).

Finally, another study revealed the presence of significantly different D3R mRNA levels in PBLs among SCZ subtypes (residual, disorganized and paranoid SCZ) per the DSM-IV criteria, leading the authors to conclude that D3R could be used as a diagnostic peripheral marker of SCZ subtypes (Uryan-Kucuk et al., 2011), although in the updated DSM-V all these different subtypes were eliminated (American Psychiatric Association, 2013).

4.2.3. D4R

In general, there are no alterations in the levels of D4R mRNA (Table 4) between SCZ patients and healthy controls in any population of leukocytes studied (Ilani et al., 2004; Rodrigues et al., 2005; Kawano et al., 2011; Ahmadian et al., 2014). However, using flow cytometry, a group of researchers observed a significant overexpression in the percentages of CD8+ D4R+ and CD4+ D4R+ T LYM from medicated SCZ patients institutionalized versus controls (Brito-Melo et al., 2012), and on the contrary, by RT-PCR was used to show a significant down-regulation of D4R mRNA in CD4+ of SCZ patients compared to sex- and age-matched controls (Boneberg et al., 2006). The authors suggest that this difference between mRNA and protein levels might be due to post-transcriptional mechanisms or because of different populational samples. Also, since the patients in all the studies were medicated, it is unlikely that this contrast of results is caused by differences in the individual pharmacological treatment (Brito-Melo et al., 2012).

Finally, a significant inverse correlation between BPRS hebbrephic dimension score and D4R expression in LYM of SCZ patients was observed (Rodrigues et al., 2005), while D4R expression was positively correlated with the working memory subscale of the Brief Assessment of Cognition in Schizophrenia Japanese-language version (BACS-J) (Kawano et al., 2011) and the AIMS score was inversely related to CD4+ D4R+ (Brito-Melo et al., 2012).

5. Conclusions

SCZ is a heterogeneous psychiatric disorder with a wide spectrum of clinical and biological manifestations. Due to the lack of objective evidence, precise diagnosis and selection of effective treatments for SCZ patients remains a challenge. Numerous technologies have been used in search of biomarkers for SCZ. However, after a century of studying SCZ their application in psychiatry remains rare and there are currently no validated biomarkers for the diagnosis and prognosis of patients with SCZ or the prediction of treatment efficacy.

Considering that in most SCZ patients suffering an acute episode, routine blood tests are usually within normal parameters, another type of analysis is necessary to detect the psychotic state. Studying DRs in the human CNS has obvious limitations. Peripheral immune cells like LYM are well-known to express all DRs on their membrane surface, and therefore, could be directly affected by DA partial agonists or antagonists, the most common antipsychotic treatment for SCZ for more than half a century. Despite the controversy, LYM are easily accessible cells from a simple blood sample, and have potential to serve as detectable peripheral molecular biomarkers to investigate neuropsychiatric diseases in living individuals. Considering the changes in DRs after taking antipsychotics, these receptors may have a physiological role, but the relationship between peripheral and central DRs is still uncertain.

This review denotes that DRs in LYM are dysregulated in certain populations of SCZ patients compared to healthy controls before taking antipsychotics and dynamically changed after taking antipsychotics, indicating that the changes in DRs expression found in SCZ patients could also result from antipsychotic medication and not from the disease itself. Further investigations into DRs in LYM are needed because they are a useful tool for evaluating the efficient properties of dopaminergic function and whether the pharmacological treatments of SCZ may be altering it. This extended analysis of the DRs status may provide the opportunity to search for factors that may account for the variance of the effect in patients, a new chance for the prediction of treatment efficiency, and detection of earlier stages of risk and prodrome of psychosis.

Table 4

| Reference            | Study                          | n  | Sample                | Methodology | Clinical features | Findings                                      |
|----------------------|--------------------------------|----|-----------------------|-------------|-------------------|-----------------------------------------------|
| Ilani et al., 2004   | Healthy controls               | 11 | PBLs                  | RT-PCR      | ND                | No differences in D4R mRNA                    |
| Rodrigues et al., 2005 | SCZ patients                  | 14 |                       |             |                   |                                               |
| Rodrigues et al., 2005 | Healthy controls              | 45 | PBLs                  | Flow-       | BPRS              | No differences in D4R protein levels           |
| Boneberg et al., 2006 | Healthy controls              | 10 | Leukocyte population | qRT-PCR     | ND                | Decreased D4R mRNA in T cells                 |
| Boneberg et al., 2006 | SCZ patients                  | 10 |                       |             |                   |                                               |
| Kawano et al., 2011  | Healthy controls               | 12 | PBLs                  | qRT-PCR     | PANSS, BACS-J, Treatment, Dose, Duration of illness | No differences in D4R mRNA D4R mRNA positively correlated with working memory scales |
| Brito-Melo et al., 2012 | Healthy controls              | 20 | LYM (CD4, CD8)        | Flow-       | CGIS, BPRS, PANSS, AIMS, Duration of illness and hospitalization, Dose of antipsychotic | Increased percentages of CD4+ D4R+ and CD8+ D4R+ cells |
| Ahmadian et al., 2014 | Drug-naïve SCZ patients       | 20 | PBLs                  | RT-PCR      | ND                | D4R expressed in all groups but no differences in mRNA |
| Ahmadian et al., 2014 | Drug-free SCZ patients (≥ 3 months) | 5  |                       |             |                   |                                               |
| Ahmadian et al., 2014 | Drug medicated SCZ patients (≥ 3 years) | 15 |                       |             |                   |                                               |
| Fernandez-Egea et al., 2016 | Healthy controls             | 18 | LYM                   | qRT-PCR     | BMI, Smoking, BACS, CGIS | No differences in D4R mRNA D4R mRNA positively correlated with working memory scales |
| Fernandez-Egea et al., 2016 | Chronic SCZ patients         | 18 |                       |             |                   |                                               |

Abbreviations: BPRS, PANSS, AIMS, AIMS, CGIS, BMI, Smoking, BACS, CGIS.
Funding

This work was supported by GAIN (Agencia Gallega de Innovación) Grant IN607D-2003/003 from the Consellería de Cultura, Educación e Ordenación Universitaria and the Consellería de Economía, Emprego e Industria (Xunta de Galicia), by Instituto de Salud Carlos III through the project PI18/01311 (co-funded by European Regional Development Fund, “A way to make Europe”) and by a Ramón & Cajal grant [RYC-2014-15246] to RCAB. The work was also supported by Instituto de Salud Carlos III, Ministerio de Economía y Competitividad [FIS P16/00405] grant to JMO.

Authors’ contributions

MAP prepared the main text, tables and figure. MAP, TR-B, DP-R, JA, AB, DA-C, CF-P, MN-A, SR-G, CB-V, HJC, JMO, RCA-B contributed to specific content of the review. JA edited the article and corrected the grammar. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank Galicia Surf Health Research Institute and the Área Sanitaria de Vigo for their support. We especially thank the Psychiatric Nursing Service and Psychiatrists at the Álvaro Cunqueiro Hospital and Nicolás Peña Hospital.

References

Abi-Dargham, A., Moore, H. 2003. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9 (5), 404–416.
Abi-Dargham, A., Rodenhizer, J., Prinzl, D., et al., 2000. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 97 (14), 8104–8109.
Ahmadian, S., Delavari, G., Ghanbari, D., Zaeefl, D., 2014. D3 as a possible marker based on D1-D4 dopamine receptors expression in paranoid schizophrenia patients. J. Mol. Biomarkers Diagn. 5, 1000171.
Amenta, F., Bronzetti, E., Felici, L., Ricci, A., Tayaebi, S.K., 1999. Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J. Auton. Pharmac. 19 (3), 151–159.
Amenta, F., Bronzetti, E., Cantalamessa, E., et al., 2001. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J. Neuroimmunol. 117 (1–2), 133–142.
American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington D.C.
Arce-Sillas, A., Sevilla-Reyes, E., Álvarez-Luquin, D.D., et al., 2019. Expression of dopamine receptors in immune regulatory cells. Neuroimmunomodulation 26 (3), 155–166.
Arreola, R., Alvarez-Herrera, S., Pérez-Sánchez, G., et al., 2016. Immunomodulatory effects mediated by dopamine. J. Immunol Res 2016, 3160486.
Barger, G., Dale, H.H., 1910. Chemical structure and sympathomimetic action of amines. American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Washington D.C.
Buttarelli, F.R., Fanucci, A., Pellicano, C., Pontieri, E.F., 2011. The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders. Curr. Neuropharmacol. 9 (2), 278–288.
Cave, J.W., Baker, H., 2009. Dopamine systems in the forebrain. Adv. Exp. Med. Biol. 651, 15–35.
Conteras, F., Prado, C., González, H., et al., 2016. Dopamine receptor D3 signaling on CD4+ T cells favors Th1- and Th17-mediated immunity. J. Immunol. 190 (16), 413–4149.
Cosentino, M., Rasiin, E., Colombo, C., et al., 2004. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic. Biol. Med. 36 (10), 1233–1240.
Cosentino, M., Fietta, A.M., Ferrari, M., et al., 2007. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autoimmunoparacrine inhibitory functional loop. Blood 109 (2), 632–642.
Cui, Y., Prabhu, V., Nguyen, T.B., Yadav, B.K., Chung, Y.C., 2015. The mRNA expression status of dopamine receptor D2, dopamine receptor D3 and DARPP-32 in T lymphocytes of patients with early psychosis. Int. J. Mol. Sci. 16 (11), 26677–26686.
Davidson, M., Harvey, P.D., Bergman, R.L., et al., 1990. Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch. Gen. Psychiatr. 47 (2), 190–191.
Emley, R., Chiliza, B., Aslam, L., Harvey, B.H., 2013. The nature of relapse in schizophrenia. BMC Psychiatr. 13, 50.
Faraji, B.A., Olikowski, Z.L., Jackson, R.T., 1991. Binding of [3H]dopamine to human lymphocytes: possible relationship to neurotransmitter uptake sites. Pharmacology 41 (S1), 135–141.
Faraji, B.A., Olikowski, Z.L., Jackson, R.T., 1994. Active [3H]dopamine uptake by human lymphocytes: correlates with serotonin transporter activity. Pharmacology 48 (5), 320–327.
Fernández-Egaña, E., Vértes, P.E., Flint, S.M., et al., 2016. Peripheral immune cell populations associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. PloS One 11 (5), e0155631.
Ferrari, M., Cosentino, M., Marino, F., et al., 2004. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes. Biochem. Pharmacol. 67 (5), 865–873.
Fletchhacker, W.W., Arango, C., Arteel, P., et al., 2014. Schizophrenia-time to commit to policy change. Schizophr. Bull. 40 (Suppl. 3), S165–S194. Suppl 3.
Francese, R., Pancholi, R., Liius, C., Abern, G.P., O’Connell, P.J., 2007. The emergence of neurotransmitters as immune modulators. Trends Immunol. 28 (9), 400–407.
Franz, D., Conteras, F., González, H., et al., 2015. Dopamine receptors D3 and D5 regulate CD4+ T-cell activation and differentiation by modulating ERK activation and AMP production. J. Neuroimmunol. 284, 18–29.
González, H., Conteras, F., Prado, C., et al., 2013. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson’s disease. J. Immunol. 190 (10), 5048–5056.
Grace, A.A., 2016. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat. Rev. Neurosci. 17 (8), 524–532.
Harmar, A.J., Hills, R.A., Rosner, E.M., et al., 2009. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res. 37 (1), D660–D669.
Howes, O.D., Kapur, S., 2009. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr. Bull. 35 (3), 549–562.
Huang, Y., Chen, C.C., Wang, T.T., Qiu, Y.H., Peng, Y.F., 2016. Dopamine receptors modulate T lymphocytes via inhibition of CAMP-CREB signaling pathway. Neuroendocrinol. Lett. 37 (7), 491–500.
Ibarri, S., Stros, R.D., Fuchs, S., 2004. Dopaminergic regulation of immune cells via D1 and D5 receptors: a pathway mediated by activated T cells. Faseb. J. 18 (13), 1600–1602.
Kandel, E.R., Schwartz, J.H., Jessell, T.M., Siegelbaum, S.A., Hudspeth, A.J., 2000. Principles of Neural Science, fifth ed. McGraw-Hill, New York.
Kawano, M., Sawada, K., Tsuru, E., et al., 2011. Dopamine receptor δ3 and δ4t mRNA levels in peripheral lymphocytes of patients with schizophrenia correlate with severity of illness. Open J. Psychiatr. 1, 33–39.
Kebabian, J.W., 1978. Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenyl cyclase. Life Sci. 23 (5), 479–483.
Kipnis, J., Cardon, M., Avidan, H., et al., 2004. Dopaminergic receptor-dependent regulation of immune cell populations associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia. PloS One 11 (5), e0155631.
Kroiz, G.P., Brukay, R.J., Dourado, M.N., Burt, R.S., 2012. Dopamine receptors in human lymphocytes: regulatory T-cell activity and quantitative RT-PCR assays. J. Neurosci. Methods 174 (2), 272–280.
Krstulovic, N., Rasini, E., Legnaro, M., Marino, F., Cosentino, M., 2014. Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease. J. Neuroimmunol. Pharm. 9 (3), 302–312.
Kwak, Y.R., Koo, H.B., Choi, C.H., Sunwoo, I., 2001. Change of dopamine receptor mRNA expression in lymphocytes of psychotic patients. BMC Med. Genet. 2, 3.
Laruelle, M., Abi-Dargham, A., Gil, R., Regele, L., Innis, R., 1999. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatr. 46 (1), 56–72.

Levite, M., 2016. Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol. 216 (1), 42–89.

Levite, M., 2012. Dopamine in the immune system: dopamine receptors in immune cells, potent effects, endogenous production and involvement in immune and neuropsychiatric diseases. In: Levite, M. (Ed.), Nerve-driven immunity – Neurotransmitters and Neuropeptides in the Immune System. Springer, Wien, pp. 1–45.

Levite, M., Chowers, Y., Ganzor, Y., Beesser, M., Henklovits, R., Cahalon, L., 2001. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta 1 integrin function. Eur. J. Immunol. 31 (12), 3504–3512.

Li, P., Snyder, G.L., Vanover, K.E., 2016. Dopamine targeting drugs for the treatment of schizophrenia: present, past and future. Curr. Top. Med. Chem. 16 (29), 3583–3605.

Lidow, M.S., Elsworth, J.D., Goldman-Rakic, P.S., 1997. Down-regulation of the D1 and D5 dopamine receptors in the prefrontal cortex by chronic treatment with antipsychotic drugs. J. Pharmacol. Exp. Therapeut. 281 (1), 597–603.

Liu, L., Yuan, G., Cheng, Z., Zhang, G., Liu, X., Zhang, H., 2013. Identification of the mRNA expression status of the dopamine D2 receptor and dopamine transporter in peripheral blood lymphocytes of schizophrenia patients. PloS One 8 (9), e75259.

Mannich, C., Jacobson, W., Hr, Mannich, 1990. Über oxyphenyl-alkylamine und dihydroxyphenyl-alkylamine. Ber. Dtsch. Chem. Ges. 43 (1), 189–197.

Marder, S.R., Cannon, T.D., 2019. Schizophrenia. N Engl J Med. 381 (18), 1753–1761.

Marino, F., Cosentino, M., Bombelli, R., Ferrari, M., Lecchini, S., Frigo, G., 1999. Endogenous catecholamine synthesis, metabolism storage, and uptake in human peripheral blood mononuclear cells. Exp. Hematol. 27 (3), 489–495.

Matt, S.M., Gaskill, P.J., 2020. Where is dopamine and how do immune cells see it? dopamine-mediated immune cell function in health and disease. J. Neuroimmune Pharmacol. 15, 114–164.

Mckenna, F., McLaughlin, P.J., Lewis, B.J., et al., 2002. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132 (1–2), 34–40.

Mignani, F., Sabbatini, M., Capaccichti, M., et al., 2013. T-cell subpopulations express a different pattern of dopaminergic markers in intra- and extra-thymic compartments. J. Biol. Regul. Homeost. Agents 27 (2), 463–475.

Millan, M.J., Agid, Y., Brüne, M., et al., 2012. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 11, 141–168.

Moreno-Küstner, B., Martín, C., Pastor, L., 2018. Prevalence of psychotic disorders and its relationship. Schizophr. Res. 197, 19–25.

Stahl, S.M., 2017a. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptors. CNS Spectr. 22 (4), 305–311.

Stahl, S.M., 2017b. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr. 22 (5), 375–384.

Rodrigues, K.P., Souza, P.A., Lima, P.M., Dutra, W.O., Corrêa, L.A., 2017. Dopamine D2 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J. Immunol. 177 (11), 7525–7529.

Sahakian, B., Asaad, W., Chakroberty, D., et al., 2006. Cutting Edge: stimulation of dopamine D4 receptors in peripheral blood lymphocytes of schizophrenia patients. J. Neuroimmunol. 132 (1–2), 85–88.

Sarkar, C., Basu, B., Chakroberty, D., et al., 2010. The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24 (4), 525–528.

Silfstein, M., van de Giessen, E., Van Snellenberg, J., et al., 2015. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 72 (4), 316–324.

Sokoloff, P., Le Poll, B., 2017. The dopamine D3 receptor, a quarter century later. Eur. J. Neurosci. 45 (1), 1–19.

Spao, P.F., Govoni, S., Trabucli, M., 1978. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv. Biochem. Psychopharmacol. 19, 155–165.

Santambrogio, L., Liparthiti, M., DeLanca, C., Georgens, S., Farle, L., 2019. D1-Dopamine receptor availability in first-episode neurological naïve psychosis patients. Int. J. Neuropsychopharmacol. 22 (7), 415–425.

Takahashi, N., Nagan, Y., Ueno, S., Saiaki, Y., Yang transporting T and B lymphocytes. J. Neuroimmunol. 132 (1–2), 34–40.

Tomasik, J., Rahmone, H., Guest, P.C., Bahn, S., 2016. Neuroimmune biomarkers in schizophrenia. Arch. Gen. Psychiatr. 44 (7), 660–667.

Urban-Kacz, M., Erdal, M.E., Ozen, M.E., Kul, S., Herken, H., 2011. Is the dopamine D3 receptor mRNA on blood lymphocytes help to for identification and subtyping of schizophrenia? Mol. Biol. Rep. 38 (4), 2569–2572.

van der Weide, J., Steijns, I.S., van der Geld, M.A.M., de Groot, P.A., 2003. D3 Dopamine receptor mRNA expression in lymphocytes: a peripheral marker for schizophrenia? Acta Neuropsychiatr. 15 (2), 91–93.

Vidal, P.M., Pacheco, R., 2020. The cross-talk between the dopaminergic and the immune system involved in schizophrenia. Front. Immunol. 11, 394.

Vogel, M., Pfeifer, S., Schau, R.T., et al., 2004. Decreased levels of dopamine D3 receptor mRNA in schizophrenia and bipolar patients. Neuropsychopharmacology 50 (4), 305–310.

Wang, W., Cohen, J.A., Wallraff, A., et al., 2019. Age-related dopaminergic innervation augments T helper type-2 allergic inflammation in the postnatal lung. Immunity 51 (6), 1102–1117 e7.

Watanabe, Y., Nakayama, T., Nagakubo, D., et al., 2006. Dopamine selectively induces migration and homing of naive CD8 T cells via dopamine receptor D3. J. Immunol. 176 (2), 848–856.

Weinberger, D.R., 1987. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44 (7), 660–667.

Weinstein, J.J., Chohan, M.O., Silfstein, M., Kegeles, L.S., Moore, H., Abi-Dargham, A., 2017. Pathway-specific dopamine abnormalities in schizophrenia. Biol. Psychiatry. 81 (1), 31–42.

Yao, Y., Schröder, J., Karlsson, H., 2008. Verification of proposed peripheral biomarkers in mononuclear cells of individuals with schizophrenia. J. Psychiatric Res. 42 (8), 693–701.

Zhou, W., Huang, Y., Liu, Z., Cao, B.B., Peng, Y.P., Qiu, Y.H., 2013. Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway. J. Neuroimmunol. 260 (1–2), 250–259.